A patient on a ventilator in an ICU gets carbapenem-resistant Acinetobacter baumannii. Before BV100 existed, the best available therapy had a 28-day mortality rate of 60%. Read that as a clinician and you understand why antimicrobial resistance (AMR) deserves serious attention. Read it as a policymaker and you should ask why we waited this long to fund Phase 3 trials.
To answer the headline directly: no, AMR does not currently kill more people than cancer. The 2019 global burden data, published in The Lancet, attributed 1.27 million deaths directly to bacterial resistance and associated it with 4.95 million more. Cancer killed roughly 10 million that same year. The gap is real. Anyone claiming AMR already surpasses cancer is misreading the numbers, and that kind of inflation actually undermines the legitimate case for urgency.
The legitimate case is this: a 2025 WHO surveillance report found that resistance rose in over 40% of monitored pathogen-antibiotic combinations between 2018 and 2023. Five years. That is not a trend you extrapolate casually; that is a trend you take seriously because the underlying mechanism, natural selection under antibiotic pressure, does not pause while we debate funding priorities.
The Projection That Should Be Keeping Ministers Awake
The 10-million-deaths-by-2050 figure circulates widely enough that critics have called it alarmist. Fair point: projections 25 years out carry enormous uncertainty, and the model assumes continued inaction. But the 2050 estimate comes from the same analytical tradition as the global burden studies that held up well when validated against observed data. Dismissing it because it is inconvenient is not skepticism; it is motivated reasoning. The projection is a conditional warning, not a prophecy, and the condition it warns against is exactly what is currently happening.
The cancer comparison also misses something structural. AMR does not compete with cancer. It amplifies it. Chemotherapy suppresses immunity. Surgical oncology requires clean operative fields. A world where resistant infections complicate cancer care is not a world where cancer mortality stays flat; it is a world where it rises. The March 18, 2026 Daily Maverick op-ed cited this directly: routine procedures, childbirth, and cancer treatment all become materially more dangerous when antibiotics fail. That interaction effect does not show up cleanly in either death toll, which means both numbers understate the combined problem.
What Progress Actually Looks Like, and Why It Is Not Enough
There is real science worth acknowledging. A recent Science Advances study demonstrated enzyme-responsive hydrogels that release antibiotics only at infection sites, with no resistance development after 10 exposure cycles in murine and porcine wound models. BioVersys's Phase 2 data for BV100 showed 28-day mortality of 25% against Acinetobacter baumannii in ventilated patients, compared to 60% for the best available therapy. These are genuine results. They are also single studies in early phases, and I will not dress up preliminary data as solved problems.
The pipeline is thin. The economics of antibiotic development remain broken because a drug used sparingly to preserve efficacy generates less revenue than a drug prescribed broadly. No pharmaceutical company fixes that math voluntarily. Governments fix it through pull incentives, subscription payment models, and public funding for late-stage trials. The UK's subscription model for antibiotics is the closest working example. The US has not replicated it at meaningful scale.
AMR is not more dangerous than cancer today. By 2050, without structural changes to how we develop, prescribe, and pay for antibiotics, the 1.27 million will become the 10 million. The evidence for that trajectory is sound. The policy response is not. That is the actual scandal.
